Clinical trial · Interventional
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Adjuvant Chemotherapy (Docetaxel and Estramustine Phosphate) for High Risk Localized Prostate Cancer
NCT00193271CI-TRIAL-00004757completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| Estramustine | Drug | Estramustine | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response Rate
Secondary outcomes (2)
- measure
- Rate of recurrence
- measure
- Toxicity
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: To be included in this study, you must meet the following criteria: * Histologically confirmed adenocarcinoma of the prostate * Clinically or surgically staged localized disease, stage I-III. * Prior surgical resection or radiation therapy with curative intent * No clinical evidence of residual disease * Gleason's combined score \> 7. * Age \> 18 years. * No prior chemotherapy for prostate cancer. * No previous androgen deprivation therapy for prostate cancer * Able to perform activities of daily living with minimal assistance * Adequate bone marrow, liver and kidney function * Voluntarily provide written informed consent. Exclusion Criteria: You cannot participate in this study if any of the following apply to you: * History of prior malignancy in the past five years * History of significant heart disease within the previous 6 months * Cerebral vascular accident (CVA) or stroke within the previous 6 months. * Moderate or severe peripheral neuropathy * Previous therapy with other injectable radioisotopes. Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
References
Publications (0)
Data not yet available
No reference posted for this study.